Acute Myeloid Leukemia With Myelodysplasia-Related Changes (DBCOND0036177)

Identifiers

Synonyms

Acute myeloid leukemia with myelodysplasia-related changes / Acute myeloid leukemia with multilineage dysplasia, not having achieved remission / Acute myeloid leukemia with multilineage dysplasia / Acute myeloid leukemia myelodysplasia related (morphologic abnormality) / Acute myeloid leukemia with myelodysplasia-related changes (disorder)

Associated Data

Indicated Drugs and Targets

Drug	Description	Targets
Cytarabine	A pyrimidine nucleoside analogue used to treat acute non-lymphocytic leukemia, lymphocytic leukemia, and the blast phase of chronic myelocytic leukemia.	DNA polymerase betatarget Cytidine deaminaseenzyme Solute carrier family 22 member 4transporter ATP-binding cassette sub-family C member 10transporter Equilibrative nucleoside transporter 1transporter DNAtarget Cytochrome P450 3A4enzyme Deoxycytidine kinaseenzyme 5'-nucleotidaseenzyme Deoxycytidylate deaminaseenzyme DNA polymerase catalytic subunittarget
Daunorubicin	An anthracycline aminoglycoside used to induce remission of nonlymphocytic leukemia and acute lymphocytic leukemia.	DNAtarget Cytochrome P450 3A5enzyme NADPH--cytochrome P450 reductaseenzyme ATP-dependent translocase ABCB1transporter Multidrug resistance-associated protein 1transporter ATP-binding cassette sub-family C member 6transporter ATP-binding cassette sub-family C member 10transporter Broad substrate specificity ATP-binding cassette transporter ABCG2transporter DNA topoisomerase 2-alphatarget DNA topoisomerase 2-betatarget Cytochrome P450 1B1enzyme Cytochrome P450 3A4enzyme Aldo-keto reductase family 1 member B1enzyme Carbonyl reductase [NADPH] 1enzyme Carbonyl reductase [NADPH] 3enzyme

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT06143839	VYxeoS Liposomal Italian Observational Study iN the Real Practice	Cytarabine Daunorubicin	Not Available	Not Available	recruiting
NCT02727803	Personalized NK Cell Therapy in CBT	Activated natural killer cell therapy Aloe vera leaf Ascorbic acid Busulfan CD-16 NK-92 cells Clofarabine Cyclophosphamide Fludarabine Glycerin Mechlorethamine Natural Killer Cell Nicotinamide Rituximab Vitamin A	treatment	2	recruiting
NCT04231851	CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia	Cytarabine Daunorubicin Glasdegib	treatment	2	active_not_recruiting
NCT04269213	CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old	Cytarabine Daunorubicin	treatment	2	recruiting
NCT03330821	Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia	Cytarabine Idarubicin Pevonedistat	treatment	1 / 2	active_not_recruiting
NCT00416598	Decitabine as Maintenance Therapy After Standard Therapy in Treating Patients With Previously Untreated Acute Myeloid Leukemia	Beta-D-Glucose Busulfan Cytarabine Daunorubicin Decitabine Etoposide Filgrastim	treatment	2	completed
NCT03526926	A Post-Marketing Observational Study of VYXEOS™	Cytarabine Daunorubicin	Not Available	Not Available	completed